Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, Hausner P, Kennedy R, Kindler H, Metintas M, Mutti L, Onda M, Pass H, Premkumar A, Roggli V, Sterman D, Sugarbaker P, Taub R, Verschraegen C
National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892-4264 USA.
Ann Oncol. 2006 Nov;17(11):1615-9. doi: 10.1093/annonc/mdl060. Epub 2006 Apr 6.
Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site for mesothelioma development and accounts for 10-20% of all mesotheliomas diagnosed in the United States. A meeting sponsored by the NIH Office of Rare Diseases was held in Bethesda, Maryland on September 13 and 14, 2004. The objective of this meeting was to review the epidemiology, biology and current surgical and medical management of peritoneal mesothelioma. In addition, the meeting also discussed clinical and pre-clinical evaluation of novel treatments for mesothelioma as well as ongoing laboratory research to better understand this disease. This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research.
腹膜间皮瘤是一种罕见的腹膜癌，在美国每年约有250例新确诊病例。它是间皮瘤发生的第二常见部位，占美国确诊的所有间皮瘤的10% - 20%。2004年9月13日和14日，美国国立卫生研究院罕见疾病办公室在马里兰州贝塞斯达主办了一次会议。本次会议的目的是回顾腹膜间皮瘤的流行病学、生物学以及当前的手术和药物治疗。此外，会议还讨论了间皮瘤新疗法的临床和临床前评估以及为更好地了解这种疾病而正在进行的实验室研究。本报告总结了会议的议程以及未来临床和基础研究的方向。
